Macular Telangiectasia Type 1: Aflibercept vs. Placebo

We are studying whether aflibercept can improve retinal thickness and vision in patients with macular telangiectasia type 1 compared to a placebo. The trial also looks at the safety of the treatment.

3-6 months 6-10 visits Confirmation phase (III)Standard Medicines InjectionOphthalmology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Eylea

Eylea is an eye injection medicine used to treat abnormal blood vessel growth and swelling that can cause vision loss in retinal diseases.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Aflibercept

Aflibercept is a substance that blocks signals that cause abnormal blood vessel growth and leakage in the eye to treat retinal diseases.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Afqlir

Ahzantive

Baiama

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Assistance Publique Hopitaux De Paris

Ophtalmology

Angers, France

Centre Hospitalier Universitaire De Toulouse

Ophtalmology

Blagnac, France

Hospices Civils De Lyon

Ophtalmology

Caluire-et-Cuire, France

Sponsor: Centre Hospitalier Universitaire De Dijon

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.